Our website uses cookies to improve your on-site experience. By using the website, cookies are being used as described in our Policy Document
Warning: To log in you will need to enable cookies and reload the page (Policy Document)
My ePortfolio Register   

ESMO 2016 /
Atezolizumab v docetaxel for NSCLC: results from the OAK trial

7th - 11th Oct 2016

Please rate this video

Please complete at least one question.

  1. The information in this video was of interest to me Disagree Agree
  2. The information in this video is likely to improve my clinical practice or research Disagree Agree
  3. I would recommend this video to my colleagues Disagree Agree
Thanks for rating
There has been a problem, please refresh and try again.
Published: 09.10.16
Views: 2427

Dr Fabrice Barlesi - Hôpital Nord, Marseille, France

Dr Barlesi presents, at a press conference at ESMO 2016, results from the OAK study, which found atezolizumab improved median overall survival for patients with advanced non-small cell lung cancer, especially those stratified by high PD-1 expression.

His interview with ecancer about the results is available here.

PD-1/PD-L1 targeting in lung cancer was also the focus of ESMO 2016 presentations from Dr Corey Langer, in which first-line pembrolizmab plus chemotherapy improved patient outcomes, and Dr Martin Reck, who reported on using pembrolizumab as a first line single-agent treatment.

Previous conferences: highlights

Founding partners

European Cancer Organisation European Institute of Oncology

Founding Charities

Foundazione Umberto Veronesi Fondazione IEO Swiss Bridge

Published by

ecancer Global Foundation